谷胱甘肽转移酶基因多态性与妇科恶性肿瘤易感性和预后的相关性研究进展

doi:10.3969/j.issn.1004-616x.2016.01.016

摘要/Abstract

摘要： 谷胱甘肽转移酶(GST)是体内重要的II相代谢酶,GST在人群中呈多态性分布,基因多态性导致酶活性降低或丧失。研究显示GST基因多态性不仅与妇科多种恶性肿瘤的易感性有关,而且会影响化疗药物对肿瘤的疗效,影响患者的预后,且结果存在差异。本文将重点阐述GST的基因多态性、GST基因分型方法的进展及GST与妇科肿瘤易感性和预后的关系。

关键词: 谷胱甘肽转移酶, 多态性, 恶性肿瘤, 易感性, 预后

中图分类号:

R730.2

黄神姣, 陈敦金, 谭鹰, 夏华安, You MJ. 谷胱甘肽转移酶基因多态性与妇科恶性肿瘤易感性和预后的相关性研究进展[J]. 癌变·畸变·突变, 2016, 28(1): 73-76.

[1] McIlwain CC,Townsend DM,Tew KD. Glutathione S-transferase polymorphisms:cancer incidence and therapy[J]. Oncogene,2006 25(11):1639-1648.
[2] Chen HC,Cao YF,Hu WX,et al. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China[J]. Dis Markers,2006,22(3):141-152.
[3] Singh H,Sachan R,Devi S,et al. Association of GSTM1,GSTT1 and GSTM3 gene polymorphisms and susceptibility to cervical cancer in a North Indian population[J]. Am J Obstet Gynecol,2008,198(3): 303-306.
[4] Townsend DM,Tew KD. The role of glutathione-S transferase in anti-cancer drug resistance[J]. Oncogene,2003,22:7369-7375.
[5] Di Pietro G,Magno LA,Rios-Santos F. Glutathione S-transferases: an overview in cancer research[J]. Expert Opin Drug Metab Toxicol 2010,6(2):153-170.
[6] Xu S,Wang Y,Roe B,et al. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion[J]. J Biol Chem,1998,273(6):3517-3527.
[7] Smith CM,Kelsey KT,Wiencke JK,et al. Inherited glutathione-S-transferase deficiency is a risk factor for pulmonary asbestosis[J]. Cancer Epidemiol Biomarkers Prev,1994,3(6):471-477.
[8] Parl F. A need for true GSTM1 and GSTT1 genotyping[J]. Cancer Epidemiol Biomarkers Prev,2009,18(10):2793.
[9] Roodi N,Dupont WD,Moore JH. et al. Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk[J]. Cancer Res,2004,64(4):1233-1236.
[10] Sprenger R,Schlagenhaufer R,Kerb R. Characterization of the glutathione S-transferase GSTT1 deletion:discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype phenotype correlation[J]. Pharmacogenetics,2000,10:557-65.
[11] Yu KD,Di GH,Fan L,et al. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer [J]. FASEB J,2009,23(7):2274-2287.
[12] Ueda M,Toji E,Nunobiki O,et al. Germline polymorphisms of glutathione-S-transferase GSTM1,GSTT1 and p53 codon 72 in cervical carcinogenesis[J]. Hum Cell,2010,23(4):119-125.
[13] Palma S,Novelli F,Padua L,et al. Interaction between glutathione S-transferase polymorphisms,smoking habit,and HPV infection in cervical cancer risk[J]. J Cancer Res Clin Oncol,2010,136(7): 1101-1109.
[14] Kiran B,Karkucak M,Ozan H,et al. GST (GSTM1,GSTT1,and GSTP1) polymorphisms in the genetic susceptibility of Turkish patients to cervical cancer[J]. J Gynecol Oncol,2010,21 (3):169-173.
[15] Natphopsuk S,Settheetham-Ishida W,Settheetham D. Lack of participation of the GSTM1 polymorphism in cervical cancer development in Northeast Thailand[J]. Asian Pac J Cancer Prev,2015,16(5): 1935-1937.
[16] Hasan S,Hameed A,Saleem S. The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan[J]. Tumour Biol,2015,36(7):5195-5199.
[17] Economopoulos KP,Choussein S,Vlahos NF. GSTM1 polymorphism GSTT1 polymorphism,and cervical cancer risk:a meta-analysis[J]. Int J Gynecol Cancer,2010,20(9):1576-1580
[18] Au WW,Sierra-Torres CH,Tyring SK. Acquired and genetic susceptibility to cervical cancer[J]. Mutat Res,2003,544(2/3):361-364.
[19] 周芩,王金桃,邵淑丽,等. GSTM1及GSTT 1基因多态性与宫颈癌关系的研究[J]. 现代预防医学,2006,33(3):269-271.
[20] 宋广叶,宋志宇,许瑾丽,等. GSTM1基因多态性与山西地区宫颈癌遗传易感性关系的研究[J]. 中华肿瘤防治杂志,2008,15(14): 1054-1056.
[21] 刘瑶,马文静,刘清,等. GSTM1、CYP2E1基因多态性与新疆维吾尔族妇女宫颈癌及癌前病变关联性的研究[J]. 现代妇产科进展,2009,18(11):840-843.
[22] Sobti RC,Kaur S,Kaur P,et al. Interaction of passive smoking with GST (GSTM1,GSTT1,and GSTP1) genotypes in the risk of cervical cancer in India[J]. Cancer Genet Cytogenet,2006,166:117-123.
[23] Baxter SW,Thomas EJ,Campbell IG. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer[J]. Carcinogenesis 2001,22(1):63-65.
[24] Spurdle AB,Webb PM,Purdie DM,et al. Polymorphisms at the glutathione S-transferase GSTM1,GSTT1 and GSTP1 loci:risk of ovarian cancer by histological subtype[J]. Carcinogenesis,2001 22(1):67-72.
[25] Gates MA,Tworoger SS,Terry KL,et al. Talc use,variants of the GSTM1,GSTT1,and NAT2 genes,and risk of epithelial ovarian cancer[J]. Cancer Epidemiol Biomarkers Prev,2008,17(9):2436-2444.
[26] Delort L,Chalabi N,Satih S,et al. Association between genetic polymorphisms and ovarian cancer risk[J]. Anticancer Res,2008 28(5B):3079-3081.
[27] Tecza K,Pamula-Pilat J,Kolosza Z et al. Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy[J]. J Exp Clin Cancer Res,2015 34(1):2.
[28] Economopoulos KP,Sergentanis TN,Vlahos NF. Glutathione S-transferase M1,T1,and P1 polymorphisms and ovarian cancer risk:a meta-analysis[J]. Int J Gynecol Cancer,2010,20(5):732-737.
[29] Legro RS,Kunselman AR,Miller SA,et al. Role of androgens in the growth of endometrial carcinoma:an in vivo animal model[J]. Am J Obstet Gynecol,2001,184(3):303-308.
[30] 杜亚飞,李利,李炎. GSTM1及GST T1基因多态性与子宫内膜癌易感性的相关性[J]. 中国实用妇科与产科杂志,2010,8(26): 623-626.
[31] Karageorgi S,Prescott J,Wong JY,et al. GSTM1 and GSTT1 copy number variation in population-based studies of endometrial cancer risk [J]. Cancer Epidemiol Biomarkers Prev,2011,20(7): 1447-1452.
[32] Ashton KA,Proietto A,Otton G,et al. Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk[J]. Cancer Epidemiol,2010,34(3):328-337.
[33] Esteller M,Garcia A,Martinez-Palones JM,et al. Susceptibility to endometrial cancer:in?uence of allelism at p53,glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci[J]. Br J Cancer,1997,75(9):1385-1388.
[34] Doherty JA,Weiss NS,Freeman RJ,et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer[J]. Cancer Epidemiol Biomarkers Prev,2005,14(2):357-366.
[35] Nagle CM,Chenevix-Trench G,Spurdle AB,et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival[J]. Eur J Cancer,2007,43(2):283-290.
[36] Beeghly A,Katsaros D,Chen H,et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival[J]. Gynecol Oncol,2006,100(2):330-337.
[37] Kim HS,Kim MK,Chung HH,et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds:a Korean population-based study[J]. Gynecol Oncol,2009,113(2):264-269.
[38] Morari EC,Lima AB,Bufalo NE,et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients[J]. J Cancer Res Clin Oncol,2006,132(8):521-528.
[39] Soh Y,Goto S,Kitajima M,et al. Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers[J]. Clin Oncol:R Coll Radiol,2005,17(4): 264-270.
[40] 王华英施达仁陆洪芬. GST-π与宫颈癌化疗敏感性及预后的关系[J]. 中国癌症杂志,2001,23(4):305-308.

谷胱甘肽转移酶基因多态性与妇科恶性肿瘤易感性和预后的相关性研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	王蕊, 王珩, 吴娟, 纪晓坤, 郭晓, 马阳, 杜芸. 全自动DNA图像分析系统在胰腺恶性肿瘤诊断中的价值[J]. 癌变·畸变·突变, 2021, 33(6): 451-454.
[5]	张宗敏. 甲状腺微小癌是否需要手术[J]. 癌变·畸变·突变, 2021, 33(5): 325-326.
[6]	陆雪梅, 许铭炎, 刘庭英, 张秋芳, 邓小玲. 潮汕地区汉族人群MTHFR基因rs1801131多态性与非综合征型唇腭裂的相关性研究[J]. 癌变·畸变·突变, 2021, 33(5): 334-337,344.
[7]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[8]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[9]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[10]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[11]	程书钧. 衰老和恶性肿瘤──防治的思考[J]. 癌变·畸变·突变, 2021, 33(3): 161-162.
[12]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[13]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[14]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[15]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.